Skip to main content
. 2018 May 15;109(6):1853–1864. doi: 10.1111/cas.13599

Figure 3.

Figure 3

Enhancer of zeste homolog 2 (EZH2) is involved in the interaction between cisplatin (cDDP) and copper transporter 1 (CTR1). A, Representative images of cellular BODIPY‐Pt accumulation (green) merged with CTR1 (red) in A2780SiEZH2, A2780SiNC, and A2780 cells treated with BODIPY‐Pt and the mean intensities of BODIPY‐Pt and CTR1 during the time course treatment. Bars represent the mean ± SD (n = 3). B, Western blot analysis for EZH2 and CTR1 in A2780 and ES2 cells receiving sequential cDDP treatment. C, Western blot analysis of EZH2 and CTR1 expression in a A2780 and ACP (a previously generated cDDP‐resistant cell line) with the treatment of cDDP (30 μmol/L) for 12 h. D, Western blot analysis of EZH2 and CTR1 expression in A2780 and ES2 cells treated with EZH2 inhibitors GSK126 (2 μmol/L for 72 h) and 3‐deazaneplanocin A DZNEP (2 μmol/L for 72 h) with the treatment of cDDP (30 μmol/L) for 12 h. E, Western blot analysis of EZH2 and CTR1 expression in A2780 and ES2 cells with scrambled control (shNC) or shEZH2 shRNA with the treatment of cDDP (30 μmol/L) for 12 h. *P < .05, **P < .01, Student's t‐test